Cardiomyopathy

Researchers found persistent and substantial delays between heart failure diagnosis and ATTR-CM identification.

A recent study identified persistent myocardial fibroblast activation in patients with heart failure with reduced ejection fraction, with distinct patterns by etiology.

A large cohort study across UK Biobank and All of Us finds RBM20 variants contribute to arrhythmogenic dilated cardiomyopathy.

Cardiac MRI tissue characterization can detect early, low-burden transthyretin cardiac amyloidosis and accurately distinguish it from similar conditions, a study found.

Vutrisiran not only slowed progression to advanced heart failure in patients with ATTR-CM but also reduced mortality and MACE among those who developed advanced disease.

Vutrisiran kept a favorable safety profile in patients with transthyretin amyloidosis treated for up to 58 months, with AE rates comparable to placebo and no new safety concerns.

A Cleveland Clinic study shows a medically trained AI system can rapidly screen electronic health records to identify eligible participants for rare disease clinical trials.

Patients with oHCM experience significant variation in cardiovascular events, health care resource use, and costs across age, sex, race, and US region.

A new Mayo Clinic study questions the benefit of implantable cardioverter-defibrillator use to treat patients with transthyretin cardiac amyloidosis.

Meaningful reductions in all-cause mortality and cardiovascular hospitalizations modeled benefits compared with untreated populations.

Experts propose a 6-parameter framework for ATTR-CM monitoring and disease progression in transthyretin amyloid cardiomyopathy.

Vutrisiran significantly reduces mortality and cardiovascular events in older patients with ATTR-CM, enhancing quality of life and functional capacity.

Adults with hypertrophic cardiomyopathy living in lower-income or more socially deprived areas experienced significantly higher risks of heart failure, arrhythmias, stroke, and death.

Adults with hypertension who have prediabetes and subclinical myocardial injury or stress face a higher risk of incident heart failure, a study suggests.

Among patients who did receive early DNAR orders, survival to hospital discharge did not differ by race or ethnicity.

The cardiac myosin inhibitor is expected to be available in the US in the second half of January 2026.

Genetics played a major role in predicting worsening LVEF, progressing to a dilated cardiomyopathy phenotype, and a combined end point of both.

Intranasal etripamil was approved to self-treat episodes of paroxysmal supraventricular tachycardia, supported by phase 3 RAPID trial data.

Long-term data suggest stress echocardiography can uncover impaired exercise capacity and predict worse outcomes in patients.

After 8 months of treatment with mavacamten, 5% of patients developed new atrial fibrillation or flutter and 4% developed heart failure.

Papillary muscle scarring has a substantial association with both cardiovascular mortality and arrhythmia.